Oral versus vaginal misoprostol administered one hour before surgical termination of pregnancy: a randomised controlled trial
Authors: Sharma, Sunita1; Refaey, Hazem1; Stafford, Michael1; Purkayastha, Sheila1; Parry, Marianne2; Axby, Helen2
Source: BJOG: An International Journal of Obstetrics & Gynaecology, Volume 112, Number 4, April 2005 , pp. 456-460(5)
Publisher: Blackwell Publishing
Abstract:
Objective To assess the efficacy of oral and vaginal misoprostol as cervical priming agents administered 1 hour before first trimester surgical termination of pregnancy. Design A randomised controlled trial. Setting Chelsea and Westminster Hospital, London. Population Pregnant women of 10 weeks or less gestation attending the termination of pregnancy clinic. Methods Ninety eligible women were recruited to the study during September 2001 and September 2002. Women were randomised to one of the three groups: misoprostol administered orally (400 μg), misoprostol administered vaginally (800 μg) and standard care (no cervical priming agent) administered prior to surgical termination of pregnancy. Under general anaesthesia, and prior to the operation, a cervical tonometer was used to determine the main outcome measures. Main outcome measures Baseline cervical dilatation and the cumulative force required to dilate the cervix from 3 to 9 mm. Results There was no significant difference in the mean baseline cervical dilation (P= 0.16) or the cumulative force required to dilate the cervix (P= 0.12) between the three randomised groups. Conclusion No cervical priming effects were detectable with oral or vaginal misoprostol administered 1 hour before first trimester surgical termination of pregnancy.Document Type: Research article
DOI: 10.1111/j.1471-0528.2005.00255.x
Affiliations: 1: Department of Obstetrics and Gynaecology, Chelsea and Westminster Hospital, London, UK 2: Marie Stopes International, London, UK

Click here for Page Help